文献速递青光眼

奥米替尼异丙酯的眼周不良反应

Periocular Adverse Reactions to Omidenepag Isopropyl.
PubMed 文献 · Am J Ophthalmol · 2021-12-20

这项非随机对照临床研究纳入100例(100眼)原发性开角型青光眼或高眼压症患者,单眼接受奥米替尼异丙酯(OMDI)或他氟前列素治疗至少6个月,由3名眼科医生判定眼睑色素沉着、睫毛增长和上睑沟加深(DUES)的发生情况,结果显示OMDI组眼周不良反应频率为0.0%至2.0%,低于他氟前列素组。

要点

  • OMDI组眼睑色素沉着、睫毛增长和DUES频率分别为0.0%、0.0%和2.0%。
  • 他氟前列素组对应频率分别为4.0%、32.0%和12.0%。
  • 仅睫毛增长在两组间差异有统计学意义(P < .0001),OMDI组更少。

核心结论

  • OMDI的眼周不良反应频率为0%至2.0%,低于他氟前列素。

研究设计与样本

  • 非随机对照临床研究,纳入100例(100眼)原发性开角型青光眼或高眼压症患者,单眼初始接受OMDI或他氟前列素治疗至少6个月。

主要发现

  • OMDI组与他氟前列素组的平均给药时长分别为10.2 ± 3.8个月和10.8 ± 4.1个月。
  • 眼睑色素沉着、睫毛增长和DUES的频率在OMDI组分别为0.0%、0.0%和2.0%,在他氟前列素组分别为4.0%、32.0%和12.0%。
  • 仅睫毛增长在两组间差异有统计学意义(P < .0001),OMDI组睫毛增长患者少于他氟前列素组。
  • 问卷主观症状中,眼睑色素沉着、睫毛增长和DUES在OMDI组分别为8.0%、2.0%和4.0%,在他氟前列素组分别为12.0%、40.0%和4.0%。
  • 多因素分析显示所用药物类型与这些不良反应相关(R = 0.38,P = .005)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the periocular adverse reactions to omidenepag isopropyl (OMDI). DESIGN: Nonrandomized comparative clinical study. METHODS: We enrolled 100 patients (100 eyes) with primary open-angle glaucoma or ocular hypertension who received initial treatment with OMDI or tafluprost in only 1 eye for ≥6 months. Photographs of the eyelids were taken on the day of the participants' visit after ≥6 months of prescription. Subsequently, 3 ophthalmologists individually determined the occurrence of eyelid pigmentation, eyelash growth, and deepening of the upper eyelid sulcus (DUES). Additionally, a questionnaire on the subjective symptoms was administered. Multivariate analysis of baseline data was performed to investigate the factors involved in adverse reactions. RESULTS: The mean duration of drug administration was 10.2 ± 3.8 and 10.8 ± 4.1 months in the OMDI and tafluprost groups, respectively. The frequencies of eyelid pigmentation, eyelash growth, and DUES were 0.0%, 0.0%, and 2.0%, respectively, in the OMDI group, whereas the corresponding values in the tafluprost group were 4.0%, 32.0%, and 12.0%. The only significant difference was that the OMDI group showed fewer patients with eyelash growth than in the tafluprost group (P < .0001). In the questionnaire, the subjective symptoms of eyelid pigmentation, eyelash growth, and DUES were 8.0%, 2.0%, and 4.0%, respectively, in the OMDI group, whereas the corresponding values in the tafluprost group were 12.0%, 40.0%, and 4.0%, respectively. Multivariate analysis revealed a correlation between the type of drug administered and these adverse reactions (R = 0.38, P = .005). CONCLUSIONS: The frequencies of periocular adverse reactions to OMDI, ranging from 0% to 2.0%, were lower than those to tafluprost.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Inoue K, Shiokawa M, Katakura S, et al. Periocular Adverse Reactions to Omidenepag Isopropyl. Am J Ophthalmol. 2021. PMID: 34942112. doi:10.1016/j.ajo.2021.12.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。